Firm
With the US privacy landscape more fragmented and active than ever and federal legislation stalled, lawyers at Sheppard Mullin explain how states are taking bold steps to define their own regimes
A vote to be held in 2026 could create Hogan Lovells Cadwalader, a $3.6bn giant with 3,100 lawyers across the Americas, EMEA and Asia Pacific
Varuni Paranavitane of Finnegan and IP counsel Lisa Ribes compare and contrast two recent AI copyright decisions from Germany and the UK
The new court has drastically changed the German legal market, and the Munich-based firm, with two recent partner hires, is among those responding
Recently published Special Focus articles
Recently published Special Focus articles
-
Sponsored by Remfry & SagarCyril Abrol of Remfry & Sagar reports that India is not confining itself to small steps as the country aims to take a giant leap in the global space race -
Sponsored by FirstLaw PCHyoun-Ja Park and Minji Ryan Kim of FirstLaw PC analyse two significant developments as South Korea attempts to strengthen its protection of trade secrets and proprietary information involving industrial and national core technologies
-
Sponsored by Anand and AnandTusha Malhotra and Tanvi Bhatnagar of Anand and Anand say technological advances such as those in AI are presenting new challenges in protecting the personality rights of celebrities in India and necessitate a delicate balancing act
-
Sponsored by Shiga International Patent OfficeMasato Iida of Shiga International Patent Office explains what types of bio inventions are deemed eligible for patent protection in Japan and draws comparisons with US practice
-
Sponsored by Shiga International Patent OfficeThe Japan Patent Office has published additional case examples designed to clarify the patentability of AI-related technology. Fumio Takahashi of Shiga International Patent Office explains the new guidance
-
Sponsored by Wanhuida Intellectual PropertyA ruling on the inventiveness of a compound patent for a prostate cancer therapeutic could help create uniform jurisprudence regarding the examination of pharmaceutical patents, says Guan Yue of Wanhuida Intellectual Property
